Hasil Pencarian (1)
small molecule | CAS: 1887014-12-1
Olutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022.[L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susce…
Kategori:
Antineoplastic AgentsBCRP/ABCG2 InhibitorsCytochrome P-450 CYP1A2 Inducers
+32
Target Protein:
Isocitrate dehydrogenase [NADP] cytoplasmic
Waktu ParuhOlutasidenib has a …
Vol. DistribusiOlutasidenib has an…
KlirensOlutasidenib has a …
Genetik
-